Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for AGMB-447 in Idiopathic pulmonary fibrosis (IPF). The expected timing is based on the latest available company guidance and may change.
04/23/26:- AGMB-447 Ph1b IPF cohort enrolling; topline data and Ph2 IPF proof-of-concept study initiation expected in 2H 2026. 08/06/26:- IPF cohort enrolled 10 participants; topline data and Ph2 initiation remain expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.